Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Treatment Priorities and Novel Therapies Journal Article
| Authors: | Ailawadhi, S.; Biru, Y.; Clavreul, S.; Miguel, M. S.; Cormier, N.; Efebera, Y.; Merz, M.; Sato, A.; Zeanah, C.; Watkins, J. L.; Farrell, J.; Goldman, E. H.; Popat, R. |
| Article Title: | Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Treatment Priorities and Novel Therapies |
| Abstract: | Purpose: With novel therapies including chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAbs), healthcare providers (HCPs) face complexities managing treatment for patients with relapsed/refractory multiple myeloma (RRMM). This study, among the largest surveys on RRMM, examined unmet needs in care access, barriers to novel therapy use, and treatment decision-making. Methods: This survey-based study (March-June 2024) enrolled 2284 participants (patients: 1301; HCPs: 983) across 7 countries. Patients with >1 relapse/progression and HCPs managing ≥3 patients were included. Data were analyzed using descriptive statistics and Χ2 tests. Results: For patients, treatment priorities included slowing disease progression (second line [2L], 47%; third or later line [≥3L], 49%), minimizing adverse events (AEs; 2L, 43%; ≥3L, 49%), and extending life (2L, 39%; ≥3L, 38%). HCPs prioritized prolonging survival and controlling disease. Younger patients (<65 vs ≥65 years) prioritized convenience (40% vs 24%; P<0.01) and avoiding referrals to new institutions for therapies (32% vs 20%; P<0.01). Across geographies, HCPs reported logistical challenges as key reasons that CAR-T (38%) or BsAb (34%) therapy was not offered. Novel therapies were offered to patients more frequently in the US vs EU (CAR-T, 84% vs 77%, P=0.023; BsAbs, 84% vs 76%, P=0.011), with a similar trend in the US vs Japan for CAR-T; however, across all geographies, few patients recalled being offered CAR-T (17%) or BsAbs (13%). Patients receiving BsAbs prioritized efficacy-related reasons (25–35%) and nonclinical factors like less time and financial impact (27–29%), whereas those who received CAR-T prioritized patient success stories (50%), efficacy-related factors (48–50%), and minimal financial burden (43%). Conclusion: This study revealed gaps in treatment priorities; patients valued quality of life and AE management, while HCPs focused on efficacy and delaying progression. There is a significant need to educate HCPs and patients on the impact of shared decision-making when considering novel treatments for RRMM. © 2025 Ailawadhi et al. |
| Keywords: | adult; aged; leukemia; unclassified drug; major clinical study; overall survival; neutropenia; hypertension; neurotoxicity; outcome assessment; antineoplastic agent; quality of life; infection; multiple myeloma; anemia; neuropathy; thrombocytopenia; peripheral neuropathy; protein; health survey; cancer therapy; rash; questionnaire; patient care; data analysis; patient compliance; remission; health care personnel; sepsis; osteoporosis; hypercholesterolemia; dry skin; decision making; disease exacerbation; surveys; osteomyelitis; cytokine release syndrome; skin irritation; patient perspectives; human; male; female; article; bispecific antibodies; b cell maturation antigen; chimeric antigen receptor immunotherapy; relapsed/refractory multiple myeloma; car-t therapy; g protein coupled receptor family c group 5 member d |
| Journal Title: | Patient Preference and Adherence |
| Volume: | 19 |
| ISSN: | 1177-889X |
| Publisher: | Dove Medical Press Ltd |
| Date Published: | 2025-01-01 |
| Start Page: | 1089 |
| End Page: | 1104 |
| Language: | English |
| DOI: | 10.2147/ppa.S496106 |
| PROVIDER: | scopus |
| PMCID: | PMC12010075 |
| PUBMED: | 40260187 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work